N,N-dimethyl-chlorocarbamate | 145522-03-8

• 分子结构分类: 有机化合物 - 有机氧化合物 - 有机含氧阴离子化合物
• 英文名称: N,N-dimethyl-chlorocarbamate
• 英文别名: chloro N,N-dimethylcarbamate
• CAS: 145522-03-8
• 化学式: C₃H₆ClNO₂
• 分子量: 123.539
• InChiKey: UQJJETUCTXJNLW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  间硝基苯酚 、 N,N-dimethyl-chlorocarbamate 在 吡啶 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 72.0h， 生成 (3-硝基苯基)N,N-二甲基氨基甲酸酯
  参考文献：
  名称：

  Novel Class of LIM-Kinase 2 Inhibitors for the Treatment of Ocular Hypertension and Associated Glaucoma

  摘要：

  The discover), of a pyrrolopyrimidine class of LIM-kinase 2 (LIMK2) inhibitors is reported. These LIMK2 inhibitors show good potency in enzymatic and cellular assays and good selectivity against ROCK. After topical dosing to the eye in a steroid induced mouse model of ocular hypertension, the compounds reduce intraocular pressure to baseline levels. The compounds also increase outflow facility in a pig eye perfusion assay. These results suggest LIMK2 may bean effective target for treating ocular hypertension and associated glaucoma.

  DOI：

  10.1021/jm901226j

文献信息

• [EN] OXINDOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF<br/>[FR] COMPOSÉS OXINDOLES ET LEURS COMPOSITIONS PHARMACEUTIQUES
  申请人：MUSC FOUND FOR RES DEV

  公开号：WO2016176420A1

  公开（公告）日：2016-11-03

  Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of degenerative diseases and disorders.

  本文提供了化合物的结构式(I)以及其药用盐，其中取代基如规范中所披露。这些化合物及含有它们的药物组合物可用于治疗退行性疾病和紊乱。
• Novel Class of LIM-Kinase 2 Inhibitors for the Treatment of Ocular Hypertension and Associated Glaucoma
  作者：Bryce A. Harrison、N. Andrew Whitlock、Michael V. Voronkov、Zheng Y. Almstead、Kun-jian Gu、Ross Mabon、Michael Gardyan、Brian D. Hamman、Jason Allen、Suma Gopinathan、Beth McKnight、Mike Crist、Yulian Zhang、Ying Liu、Lawrence F. Courtney、Billie Key、Julia Zhou、Nita Patel、Phil W. Yates、Qingyun Liu、Alan G. E. Wilson、S. David Kimball、Craig E. Crosson、Dennis S. Rice、David B. Rawlins

  DOI：10.1021/jm901226j

  日期：2009.11.12

  The discover), of a pyrrolopyrimidine class of LIM-kinase 2 (LIMK2) inhibitors is reported. These LIMK2 inhibitors show good potency in enzymatic and cellular assays and good selectivity against ROCK. After topical dosing to the eye in a steroid induced mouse model of ocular hypertension, the compounds reduce intraocular pressure to baseline levels. The compounds also increase outflow facility in a pig eye perfusion assay. These results suggest LIMK2 may bean effective target for treating ocular hypertension and associated glaucoma.